3 Expected Pharmaceutical IPOs In 2022

As the new year 2022 unfolds, the market is ready to welcome new IPOs, it's time for old and new market participants to welcome them. In the market, as an investor, this year the share market is expected to be overwhelmed with the IPOs. Holding on to the shares or letting them go after the IPO is what will matter in 2022 for investors. As the IPO writes its growth story and based on how you want to shape your investing journey will also matter. Several unlisted firms would be attempting to get into the stock market. You may be able to take advantage of cheaper IPO rates if you are a retail investor.

Talking about the IPOs, three pharmaceutical companies are using the initial public offering (IPO) market to raise significant funds in 2022, owing to strong investor interest in the healthcare industry. Emcure Pharma's IPO, Skanray Technologies IPO, and VLCC Healthcare's IPO are all on the list.

Emcure Pharma

Emcure Pharmaceuticals is India's 12th largest pharmaceutical company, with revenues in the gynecology, blood, and HIV antivirals therapeutic areas. It controls 51.53 percent of the HIV market. It is involved in the development, manufacture, and marketing of a wide range of pharmaceutical products in a variety of therapeutic areas across the world.

Emcure Pharmaceuticals has filed a DRHP with SEBI for an IPO of between Rs.4500 Cr and Rs.5000 Cr. The IPO would be carried out by a fresh issue of equity shares worth Rs. 1,100 Cr and an offer of sale by the promoters and present shareholders. A pre-IPO placement of up to Rs.200 Cr is also being considered by the firm. If the pre-IPO goes well, the size of the IPO will be reduced. The proceeds of the new offering will be used to pay down debt and for other company operations.

VLCC Healthcare

According to market sources, VLCC Health Care Ltd, one of India's leading domestic beauty and wellness enterprises, has got approval from capital markets regulator Sebi to float its IPO. VLCC Health Care, which was founded in 1989, is today a well-known provider of wellness and beauty services and products. In the previous three decades, the brand has become a household name as well as a leader in the wellness market. VLCC's mission of "transforming lives" has been realized with consumers in over 12 countries. 

During the past 2 years of the Covid-19 epidemic, the company's focus on service performance and customer engagement helped it increase repeat customer sales. As a result, in the financial year ending March 2021, they declared a profit of Rs 6.24 crore on sales of Rs 532.92 crore.

Skanray Technologies

Another business that has filed a DRHP with SEBI valued over Rs.400 crore is Skanray Technologies. A fresh issue of Rs.400 crore and an offer for the sale of equity shares are included in the IPO. A pre-IPO placement, which involves a new issuance and an offer of sale, is also being considered by the firm. The proceeds of the new issuance will be utilized to support the company's inorganic development objectives, working cash requirements, investments in the company's subsidiaries, and capital expenditures.

Skanray Technologies has a dominant presence in the medical device sector in India. The company's major focus is on medical equipment development, design, manufacturing, and marketing. Skanray's portfolio is quite diverse, with three main categories: radiological equipment, critical care solutions, and respiratory management systems. The firm has an effective in-house R&D team that has been issued 49 trademarks, 27 patents, and 11 design registrations as of the year ending 2020. 

Disclaimer

Investment in Stock or IPos are subject to market risk. Read all documents and scheme-related conditions carefully before investing. The above-mentioned information is purely informational available at offical sources. The Greynium Information Technologies and the author are not liable for any losses caused as a result of a decision based on the article.